Lance R. Peterson , MD, FASCP

• Undergraduate: BS, Chemistry, University of Minnesota
• Medical School: MD, University of Minnesota
• Internship: St. Paul-Ramsey Medical Center, Minneapolis
• Residency: Internal Medicine, University of Minnesota Hospitals, Minneapolis
• Fellowship: Infectious Diseases and Clinical Microbiology, VA Medical Center, Minneapolis

His research interests have included the study of infections in the extremities of diabetic patients; investigations of antimicrobial agents in models that simulate closed space, neutropenic infections; the epidemiology of nosocomial pathogens (particularly MRSA, enterococci, and Clostridium difficile); the development and evaluation of new molecular diagnostic testing; measuring activity of new compounds against bacteria and fungi; and the study of the molecular mechanisms for the resistance of staphylococci and pneumococci to the new fluoroquinolone antimicrobial agents. Current research activities focus on using molecular testing methods to enhance infection control activities; understanding the regulation of antimicrobial agent resistance in enterococci, pneumococci, and staphylococci; designing new strategies for treatment of infections due to resistant bacteria; and developing new diagnostic tests for rapidly detecting microbial pathogens.

• Elected to Best doctors in America (1996).
• Recognized in the 21st Century Editions of Marquis' Who's Who

• Past President, North Central Chapter of the Infectious Diseases Society of America
• Former Chief of the Clinical Microbiology Section, and infectious diseases consultant, VA Medical Center, Minneapolis.
• Former Director, Clinical Microbiology Lab, and Infectious Diseases Consultant, Northwestern Memorial Hospital, Chicago.
• Former Chairman of the Pharmacy and Therapeutics Committee, and later the Infection Control Committee, VA Medical Center, Minneapolis.
• Former appointment as the first Director of the Northwestern Prevention Epicenter, a CDC network of academic hospitals, Chicago.
• Diplomate of the American Board of Internal Medicine, the Subspecialty of Infectious Diseases.
• Special Competency in Medical Microbiology examinations of the American Board of Pathology.
• Fellow of the Infectious Diseases Society of America.
• Fellow of the American Society of Clinical Pathology.
• Member of the American Society for Microbiology.
• Member of the British Society for Antimicrobial Chemotherapy.
• Over 500 scientific publications/presentations.

Publications in Peer-Review Journals:

1. Price, C.S., Paule, S., Noskin, G.A., and Peterson, L.R.  Active surveillance reduces vancomycin-resistant enterococci (VRE) bacteremia.  Clin. Infect. Dis. 37:921-928, 2003.
2. Paule, S.M., Trick, W.E., Tenover, F.C., Lankford, M., Cunningham, S., Stosor, V., Cordell, R.L., and Peterson, L.R.  Comparison of polymerase chain reaction to culture for surveillance detection of vancomycin-resistant enterococci.  J. Clin. Microbiol. 41:4805-4807, 2003.
3. Hacek, D.M., Cordell, R.L., Noskin, G.A., and Peterson, L.R.  Computer-assisted surveillance for detecting clonal outbreaks of nosocomial infection. J. Clin. Microbiol. 42:1170-1175, 2004.
4. Paule, S.M., Pasquariello, A.C., Hacek, D.M., Gavin, P.J., Fisher, A.G., Thomson Jr., R.B., Kaul, K.L., and Peterson, L.R.  Direct detection of Staphylococcus aureus from adult and neonate nasal swab specimens using real-time polymerase chain reaction.  J. Molec. Diag. 6:191-196, 2004.
5. Trick, W.E., Paule, S.M., Cunningham, S., Cordell, R.L., Lankford, M., Solomon, S.L., and Peterson, L.R.  Detection of vancomycin-resistant enterococci before and after antimicrobial therapy: Use of conventional culture and PCR.  Clin. Infect. Dis. 15:780-786, 2004.
6. Peterson, L.R., and Dalhoff, A.  Towards targeted prescribing: Will the cure for antimicrobial resistance be specific, directed therapy through improved diagnostic testing?  J. Antimicrob. Chemother. 53:902-5, 2004.
7. Lee, T.A., Hacek, D. M., Stroupe, K.T., Collins, S.M., and Peterson, L.R.  Three surveillance strategies for vancomycin-resistant enterococci in hospitalized patients:  Detection of colonization efficiency and a cost effectiveness model.  Infect. Control Hosp. Epid. 26:39-46, 2005.
8. Mangold, K.A., Manson, R.U., Koay, E.S., Stephens, L., Regner, M., Thomson, R.B. Jr., Peterson, L.R., and Kaul, K.L.  Real-time PCR for detection and identification of Plasmodium spp.  J Clin Microbiol. 43:2435-2440, 2005.
9. Paule, S.M., Pasquariello, A.C, Thomson Jr., R.B., Kaul, K.L., and Peterson, L.R.  Real-Time PCR can rapidly detect methicillin-susceptible and methicillin-resistant Staphylococcus aureus directly from positive blood culture bottles.  Am. J. Clin. Pathol. 124:404-407, 2005.
10. Peterson, L.R.  Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance.  Clin. Microbiol. Infect. 5(Oct;11 Suppl):4-16, 2005.
11. Brossette, S.E., Hacek, D.M., Gavin, P.J., Kamdar, M.A., Gadbois, K.D., Fisher, A.G., and Peterson, L.R.   A laboratory-based, hospital-wide, electronic marker for nosocomial infection:  The future of infection control surveillance?  Am J Clin Pathol. 125:34-39, 2006.
12. Peterson, L.R.  Penicillins for the therapy of pneumococcal pneumonia: Does in vitro resistance really matter?  Clin. Infect.Dis. 42:224-233, 2006.
13. Peterson, L.R., and Singh, K.  Universal patient disinfection as a tool for infection Control: rub-a-dub-dub, no need for a tub.  Arch. Int. Med. 166:274-276, 2006.
14. Peterson, L.R.  Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline.  Diagn. Microbiol. Infect. Dis. 52:163-164, 2005.
15. Gavin, P.J., Bolden, Jr., J.R., Peterson, L.R., and Thomson, Jr., R.B.  Does identification of an extended spectrum beta-lactamase (ESBL) producing organism by the microbiology laboratory influence patient management.  Infect. Dis. Clin. Pract. 14:81-83, 2006.
16. Gavin, P.J., Suseno, M.T., Thomson Jr., R.B., Gaydos, J.M., Pierson, C.L., Halstead, D.C., Aslanzadeh, J., Brecher, S., Rotstein, C., Brossett, S.E., and Peterson, L.R.  Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against ESBL-producing Escherichia coli and Klebsiella species.  Antimicrob. Agents Chemother. 50:2244-2247, 2006.